Email this page

Print this page

Report

Aurora B kinase inhibition in mitosis: Strategies for optimizing the use of Aurora kinase inhibitors such as AT9283

Jayne Curry, Hayley Angove, Lynsey Fazal, John Lyons, Matthias Reule, Neil Thompson and Nicola Wallis

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

Aurora kinases play a key role in regulating mitotic division and are attractive oncology targets.  AT9283, a multi-targeted kinase inhibitor with potent activity against Aurora A and B kinases, inhibited growth and survival of multiple solid tumor cell lines and was efficacious in mouse xenograft models.  AT9283-treatment resulted in endoreduplication and ablation of serine-10 histone H3 phosphorylation in both cells and tumor samples, confirming that in these models it acts as an Aurora B kinase inhibitor. In vitro studies demonstrated that exposure to AT9283 for one complete cell cycle committed an entire population of p53 checkpoint-compromised cells (HCT116) to multinucleation and death whereas treatment of p53 checkpoint-competent cells (HMEC, A549) for a similar length of time led to a reversible arrest of cells with 4N DNA.  Further studies in synchronized cell populations suggested that exposure to AT9283 during mitosis was critical for optimal cytotoxicity.  We therefore investigated ways in which these properties might be exploited to optimize the efficacy and therapeutic index of Aurora kinase inhibitors for p53 checkpoint compromised tumors in vivo.  Combining Aurora B kinase inhibition with paclitaxel, which arrests cells in mitosis, in a xenograft model resulted in promising efficacy without additional toxicity.  These findings have implications for optimizing the efficacy of Aurora kinase inhibitors in clinical practice.

Authors

Jayne Curry Corresponding author: j.curry@astex-therapeutics.com

Astex Therapeutics Ltd.; Cambridge, UK

Hayley Angove

Domainex Ltd.; Cambridge, UK

Lynsey Fazal

Astex Therapeutics Ltd.; Cambridge, UK

John Lyons

Astex Therapeutics Ltd.; Cambridge, UK

Matthias Reule

Merck Serono Research; Darmstadt, Germany

Neil Thompson

Astex Therapeutics Ltd.; Cambridge, UK

Nicola Wallis

Astex Therapeutics Ltd.; Cambridge, UK

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.